Ignite Creation Date:
2024-05-06 @ 2:28 PM
Last Modification Date:
2024-10-26 @ 1:31 PM
Study NCT ID:
NCT04320719
Status:
COMPLETED
Last Update Posted:
2020-05-14
First Post:
2019-12-11
Brief Title:
Optimizing Statin Tratment in People Living With Diabetes
Sponsor:
University Hospital Montpellier
Organization:
University Hospital Montpellier
Study Overview
Official Title:
Medico-pharmaceutical Collaboration in Optimizing Statin Tratment in People Living With Diabetes
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MEDPHARM-RCV
Brief Summary:
Hypercholesterolemia is frequent prevalence of 30 in general population and constitue with diabetes obesity and arterial hypertension a major risk factor of atherosclerosis that leads to cardiovascular diseases CVD Cardiovascular disease CVD due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years in Europe and is also increasingly common in developing countries In the European Union the economic cost of CVD represents annually 192 billion in direct and indirect healthcare costs The main clinical entities are coronary artery disease CAD ischaemic stroke and peripheral arterial disease PAD The causes of these CVDs are multifactorial Some of these factors relate to lifestyles such as tobacco smoking lack of physical activity and dietary habits and are thus modifiable Other risk factors are also modifiable such as elevated blood pressure type 2 diabetes and dyslipidaemias or non-modifiable such as age and male gender LDL-cholesterol LDL-C is one of the major risk factors for CVD through its role in the development of atherosclerosis The efficacy of statins has been demonstrated by a considerable amount of literature not only in lowering LDL cholesterol levels but also in reducing cardiovascular events both in diabetes and non-diabetes patients Guidelines for the management of dyslipidemia have emerged from different countries Thereby in 2016 the French Society of Endocrinology SFE and the New French Society of Atherosclerosis NSFA published a consensus statement on the management of dyslipidemias integrating features from European recommendations However LDL-C goal attainment has rarely been assessed specifically in diabetes population in which CVD is of particular importance
This study aimed to assess the rate of patients which requiered an management in cardiovascular risk treatment according to european recommendations
This observationnal study was carried in Diabetes-Nutrition unit of the University Hospital of Montpellier - France Data of age sex tobacco smoking body mass index hypertension presence and type of CVD coronary artery disease stroke peripheral arterial disease treatment by statins intensity molecule dosage diabetes complicaion nephropathy retinopathy were collected at admission Management of cardiovasculare risk treatment initiation modificiation of dosage molecule or others were collected during hospitalization and at discharge of hospitalization LDL-C HDL-C and triglycerides levels calculated with the Friedewald formula and glomerular filtration rate calculated according to the CKD-EPI formula were obtained from blood samples taken within 24 hours of hospitalization admission Cardiovascular risk level and LDL-c target values were definied according to ESC guidelines
This study aimed to assess the rate of patients which requiered an management in cardiovascular risk treatment according to european recommendations
This observationnal study was carried in Diabetes-Nutrition unit of the University Hospital of Montpellier - France Data of age sex tobacco smoking body mass index hypertension presence and type of CVD coronary artery disease stroke peripheral arterial disease treatment by statins intensity molecule dosage diabetes complicaion nephropathy retinopathy were collected at admission Management of cardiovasculare risk treatment initiation modificiation of dosage molecule or others were collected during hospitalization and at discharge of hospitalization LDL-C HDL-C and triglycerides levels calculated with the Friedewald formula and glomerular filtration rate calculated according to the CKD-EPI formula were obtained from blood samples taken within 24 hours of hospitalization admission Cardiovascular risk level and LDL-c target values were definied according to ESC guidelines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None